Compare KRUS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | EOLS |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.6M | 444.0M |
| IPO Year | 2019 | 2018 |
| Metric | KRUS | EOLS |
|---|---|---|
| Price | $58.73 | $5.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $84.29 | $20.50 |
| AVG Volume (30 Days) | 300.4K | ★ 891.1K |
| Earning Date | 01-07-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $282,763,000.00 | ★ $285,823,000.00 |
| Revenue This Year | $18.91 | $14.24 |
| Revenue Next Year | $20.16 | $21.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.88 | 15.10 |
| 52 Week Low | $40.03 | $5.71 |
| 52 Week High | $106.60 | $17.12 |
| Indicator | KRUS | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 29.49 |
| Support Level | $50.73 | $6.57 |
| Resistance Level | $56.62 | $6.80 |
| Average True Range (ATR) | 2.68 | 0.27 |
| MACD | 0.45 | -0.12 |
| Stochastic Oscillator | 87.19 | 6.23 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.